After a July rally built on hopes of a licensing deal for its lead lupus drug, ImmuPharma’s shares have swung sharply lower again — a reminder that this is a pre-revenue biotech whose fortunes still hinge on a Partnership that has yet to be signed. With a slim Balance Sheet and a story that has kept believers waiting for the best part of two decades, every gyration in the price tests the resolve of a loyal retail following.

What happened to the shares?

ImmuPharma (LSE:IMM) has once again reminded shareholders how violently a micro-cap drug developer can move. The stock, which trades in low single-digit pence, gave back a chunk of its recent gains in a sharp one-day drop that a screener flagged at roughly 18%. That fall follows a very different session in mid-July, when the shares surged around 20% on renewed optimism about a potential licensing agreement for its flagship asset, P140 (also known by the trade name Lupuzor).

The swing is best understood in context. Through much of 2026 the shares have traded below the 6 pence price at which the company raised fresh money in April, changing hands nearer 4 pence over the summer and valuing the Business at roughly £27 million around the time of the July spike, according to commentary from Kalkine. On that base, an 18% move represents a fraction of a penny in absolute terms — the kind of amplitude that is routine for a stock of this size, where thin Liquidity means modest buying or selling can shunt the quote around dramatically. What looks alarming as a percentage can be a handful of trades in practice.

For long-term holders, the more meaningful frame is not a single session but the trajectory. ImmuPharma has been a byword for Volatility on AIM for years, and the latest Reversal fits a familiar rhythm: a burst of enthusiasm on partnering hopes, followed by a pullback as traders bank profits and the market returns to waiting for hard news.

What is driving the story?

No single confirmed company-specific catalyst for the latest share-price movement was identified from the available public information.

There was no regulatory announcement, profit warning, placing or trial result timed to the drop that could be found in public sources. In the absence of a fresh disclosure, the most plausible reading is prosaic: the shares had run up around 20% in July on hopes that talks over P140 were advancing, and a Retracement of that gain is entirely consistent with normal profit-taking in an Illiquid micro-cap. Biotech stocks at this stage of development often trade on sentiment and momentum rather than newsflow, and a move of this magnitude does not require a specific trigger.

It is worth stressing what the market is really pricing. ImmuPharma has repeatedly signalled that a licensing or partnering deal for P140 is the central prize — the event that management argues could transform the company’s finances and de-risk its story. Until such a deal is signed, the shares are effectively a bet on that outcome, and they will remain acutely sensitive to any shift in perceived odds. When no confirmatory news arrives to justify a rally, gravity tends to reassert itself.

Latest company developments

The near-term narrative is dominated by P140, an immunomodulatory peptide that ImmuPharma has spent years developing as a treatment for systemic lupus erythematosus and other autoimmune conditions. In March 2026 the company issued a P140 programme update, describing work to generate new mechanistic data, strengthen Patent protection and prepare the platform for later-stage development and, crucially, for licensing. Management has consistently framed 2026 as the year in which it hopes to convert “strong pharma interest” into a concrete transaction, having previously extended the expected timeline into this year.

The July flurry of optimism — the roughly 20% jump — stemmed from signals that partnering discussions were progressing, though no binding agreement was announced. That distinction matters: interest and active talks are not the same as a signed, funded deal, and the market’s willingness to pay up and then retreat reflects exactly that uncertainty.

Beyond lupus, ImmuPharma has been building out a second string. On 10 August 2026 it appointed Kymos Group as its bioanalytical contract research partner for Kapiglucagon, a water-soluble glucagon prodrug designed to work with pumps for continuous delivery in artificial-pancreas systems for Type 1 diabetes. The programme, which also involves collaborations with names such as Thermo Fisher and Bachem for manufacturing, has moved into IND-enabling studies, with the company evaluating the US 505(b)(2) regulatory pathway. Kapiglucagon broadens the pipeline beyond a single autoimmune asset, though it remains early stage and years from any potential revenue.

Corporate housekeeping has also featured: shareholders backed all resolutions at the 2026 AGM, and the company has spoken of 2026 as a potential “year of delivery.”

Financial position

ImmuPharma is a classic pre-revenue clinical-stage developer, which means the balance sheet — not an income statement — is where the real risk sits. In results covering the 2025 financial year, reported on 27 May 2026, the company narrowed its loss to about £1.8 million, from roughly £2.5 million the year before, while Research and Development spending held broadly steady at around £1.3 million. That narrowing reflects a leaner, more focused operation rather than any commercial breakthrough.

Cash is the pressure point. The company reported ending the period with about £1.4 million, up from a wafer-thin £0.2 million previously — a level that underlines how close to the edge the group had been operating. The relief valve came in April 2026, when ImmuPharma completed a £6.47 million Equity raise priced at 6 pence per share. That injection materially strengthened the balance sheet and buys the company time, but it came at a cost familiar to long-suffering holders: dilution, and a placing price that the shares have since struggled to hold above.

The arithmetic is straightforward. With annual cash burn in the region of a couple of million pounds, the April proceeds provide a runway measured in a small number of years rather than months — enough to keep the P140 licensing effort and the Kapiglucagon programme moving, but not indefinitely. That backdrop is precisely why a licensing deal carries such weight: it would ideally bring upfront cash and milestone payments, easing the need to keep returning to shareholders for money.

The bull case

The optimistic argument rests on optionality. P140 has a long clinical history and an established safety profile, and ImmuPharma has continued to reinforce its intellectual property and mechanistic evidence — the kind of groundwork a larger partner would scrutinise before signing. If a credible pharmaceutical company were to license the asset, the Economics could dwarf the current £20-30 million-ish market value, delivering upfront cash, milestones and royalties that would recast the Investment case overnight. Bulls also point to the second pipeline pillar, Kapiglucagon, addressing a genuine unmet need in Type 1 diabetes management, and to the April fundraise, which removes the immediate spectre of a cash crunch. For risk-tolerant investors, the shares offer leveraged exposure to a binary but potentially transformational event.

The bear case

The bear case is equally clear-eyed. ImmuPharma has been promising a value-crystallising deal for a long time, and the timeline has slipped more than once — most recently pushed into 2026. Talks advancing is not a signed contract, and biotech partnering negotiations frequently collapse or drag on far longer than management hopes. The company remains loss-making, consumes cash every year, and has repeatedly diluted shareholders to stay funded; the April placing at 6 pence is only the latest example, and the shares trade below it. Liquidity is thin, the valuation is speculative, and both lead programmes still carry substantial clinical and regulatory risk. If no licensing deal materialises, the market may eventually Demand yet another Capital raise on unfavourable terms.

What could move the shares next?

The single biggest potential catalyst is unambiguous: a signed licensing or partnering agreement for P140. Confirmation of a deal — particularly one with upfront cash and a recognised counterparty — would likely trigger a substantial re-rating, while a collapse in talks could do the opposite. Short of that, investors should watch for further P140 programme updates, progress and any IND filing on Kapiglucagon, and the company’s next set of financial figures for evidence on cash burn and runway. Any hint of a fresh fundraise would also weigh on sentiment. Given the stock’s history, expect continued outsized moves on relatively modest newsflow.

Investor takeaway

ImmuPharma (LSE:IMM) remains what it has been for years: a high-risk, high-reward clinical-stage biotech whose valuation is dominated by a single unrealised event. The latest 18% drop appears to owe more to profit-taking and thin liquidity after a July rally than to any confirmed negative development. The April raise has bought breathing room, the pipeline has broadened with Kapiglucagon, and management insists a P140 deal is within reach — but the company is still loss-making, cash-consuming and dependent on a partnership that has yet to be signed. Whether investor patience is running out is, ultimately, a question each Shareholder must weigh against their own tolerance for binary, speculative situations. None of the above is a recommendation to buy or sell; anyone considering the shares should do their own research and consider taking professional advice.